

**THE BOTTOM LINE**

---

- e187**     **Can Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predict Chimeric Antigen Receptor T Cell Adverse Effects?**  
*Jie Wang, Ahmed Galal*
- e189**     **Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease?**  
*Sumithira Vasu, Samantha Jaglowski*

**REPORT**

---

- e191**     **Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report**  
*Jaleel Mohammed, Sean R. Smith, Linda Burns, Grzegorz Basak, Mahmoud Aljurf, Bipin N. Savani, Helene Schoemans, Zinaida Peric, Naeem A. Chaudhri, Nnenna Chigbo, Arun Alfred, Hadeel Bakhsh, Nina Salooja, Amah Chris Chim, Shahrukh K. Hashmi*

**REVIEW**

---

- I055**     **Salivary Changes before and after Hematopoietic Stem Cell Transplantation: A Systematic Review**  
*Stephanie J.M. van Leeuwen, Carin M.J. Potting, Marie-Charlotte D.N.J.M. Huysmans, Nicole M.A. Blijlevens*

**BIOLOGY**

---

- I062**     **The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models**  
*Kenneth A. Fowler, Kelin Li, Christopher B. Whitehurst, Danny W. Bruce, Nathaniel J. Moorman, Jeffrey Aubé, James M. Coghil*
- I075**     **Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes**  
*Mojibade Hassan, Alina Ulezko Antonova, Jian Ming Li, Sakura Hosoba, Manali Rupji, Jeanne Kowalski, Adam J. Perricone, David L. Jaye, Henry Marsh, Michael Yellin, Steven Devine, Edmund K. Waller*

## BIOMARKERS

---

- I 085**     **Glucagon-Like Peptide-I Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation**  
*Maria Schou Ebbesen, Hannelouise Kissow, Bolette Hartmann, Kathrine Grell, Jette Sønderkov Gørløv, Katrine Kielsen, Jens Juul Holst, Klaus Müller*

## CELLULAR THERAPY

---

- I 092**     **Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma**  
*Jiasheng Wang, Yongxian Hu, Shuye Yang, Guoqin Wei, Xin Zhao, Wenjun Wu, Yanlei Zhang, Yafei Zhang, Donghe Chen, Zhao Wu, Lei Xiao, Alex Hongsheng Chang, He Huang, Kui Zhao*

## AUTOLOGOUS

---

- I 099**     **Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades**  
*Deepak Kilari, Anita D'Souza, Raphael Fraser, Muna Qayed, Omar Davila, Vaibhav Agrawal, Miguel Angel Diaz, Saurabh Chhabra, Jan Cerny, Edward Copelan, Noshah Farhadfar, Cesar O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Gerhard C. Hildebrandt, Leona Holmberg, Rammurti T. Kamble, Prashant Kapoor, Hillard Lazarus, Cindy Lee, Hemant S. Murthy, Seema Naik, Taiga Nishihori, Ayman Saad, Bipin N. Savani, Sachiko Seo, Anne Warwick, Baldeep Wirk, Jean A. Yared, Yago Nieto, Parameswaran Hari*
- I 107**     **BEAM versus BUCYVP 16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma**  
*Sara Singer, Robert Dean, Qihong Zhao, Nidhi Sharma, Donna Abounader, Patrick Elder, Craig C. Hofmeister, Don M. Benson, Ashley Rosko, Sam Penza, Leslie Andritsos, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Brian Bolwell, Brad Pohlman, Matt Kalaycio, Deepa Jagadeesh, Brian Hill, Ronald Sobecks, Steven M. Devine, Navneet S. Majhail, Yvonne A. Efebera*

## ALLOGENEIC – ADULT

---

- I 116**     **Fludarabine/Melphalan 100 mg/m<sup>2</sup> Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis**  
*Han-Seung Park, Jung-Hee Lee, Je-Hwan Lee, Eun-Ji Choi, Sun-Hye Ko, Miese Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo-Hyung Lee*

- I 122**     **Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse**  
*Masumi Ueda, Najla El-Jurdi, Brenda Cooper, Paolo Caimi, Linda Baer, Merle Kolk, Lauren Brister, David N. Wald, Folashade Otegbeye, Hillard M. Lazarus, Brenda M. Sandmaier, Basem William, Yogen Saunthararajah, Philip Woost, James W. Jacobberger, Marcos de Lima*
- I 128**     **Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide**  
*Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Ivana Gojo, B. Douglas Smith, Douglas E. Gladstone, Javier Bolaños-Meade, Ivan Borrello, William H. Matsui, Lode J. Swinnen, Carol Ann Huff, Robert A. Brodsky, Richard F. Ambinder, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik*
- I 136**     **Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation**  
*Michael Scordo, Meier Hsu, Ann A. Jakubowski, Gunjan L. Shah, Christina Cho, Molly A. Maloy, Scott T. Avecilla, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Hugo Castro-Malaspina, Roni Tamari, Richard J. O'Reilly, Miguel-Angel Perales, Sergio A. Giral, Brian C. Shaffer*
- I 142**     **Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis**  
*Roni Tamari, Franck Rapaport, Nan Zhang, Caroline McNamara, Andrew Kuykendall, David A. Sallman, Rami Komrokji, Andrea Arruda, Vesna Najfeld, Lonette Sandy, Juan Medina, Rivka Litvin, Christopher A. Famulare, Minal A. Patel, Molly Maloy, Hugo Castro-Malaspina, Sergio A. Giral, Rona S. Weinberg, John O. Mascarenhas, Ruben Mesa, Damiano Rondelli, Amylou C. Dueck, Ross L. Levine, Vikas Gupta, Ronald Hoffman, Raajit K. Rampal*
- I 152**     **Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation**  
*Sayako Yuda, Shigeo Fujii, Akio Onishi, Takashi Tanaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Takahiro Fukuda*
- I 158**     **Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability**  
*Fotios V. Michelis, David W. Hedley, Sonal Malhotra, Sue Chow, David Loach, Vikas Gupta, Dennis D. Kim, John Kuruvilla, Jeffrey H. Lipton, Auro Viswabandya, Hans A. Messner*

## PEDIATRIC

---

- I 164**     **Dynamics of the Gut Microbiota in Children Receiving Selective or Total Gut Decontamination Treatment during Hematopoietic Stem Cell Transplantation**  
*Vincent Bekker, Romy D. Zwittink, Cornelis W. Knetsch, Ingrid M.J.G. Sanders, Dagmar Berghuis, Peter J. Heidt, Jaak M.J.J. Vossen, Willem M. de Vos, Clara Belzer, Robbert G.M. Bredius, Peter J. van't Hof, Arjan C. Lankester, Ed J. Kuijper*
- I 172**     **Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis**  
*Tony H. Truong, Jason D. Pole, Henrique Bittencourt, Tal Schechter, Geoff D.E. Cuvelier, Kristjan Paulson, Meera Rayar, David Mitchell, Kirk R. Schultz, Debbie O'Shea, Randy Barber, Donna Wall, Lillian Sung*
- I 179**     **Nonmyeloablative Matched Sibling Donor Hematopoietic Cell Transplantation in Children and Adolescents with Sickle Cell Disease**  
*Gregory M.T. Guilcher, Dania A. Monagel, Alberto Nettel-Aguirre, Tony H. Truong, Sunil J. Desai, Aisha Bruce, Ravi M. Shah, Michael T. Leaker, Victor A. Lewis*

## CORD BLOOD

---

- I 187**     **Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation**  
*Masamichi Isobe, Takaaki Konuma, Seiko Kato, Susumu Tanoue, Mai Mizusawa, Maki Oiwa-Monna, Satoshi Takahashi, Arinobu Tojo*

## HAPLOIDENTICAL

---

- I 197**     **Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative**  
*Josu de la Fuente, Nathalie Dhedin, Tatsuki Koyama, Françoise Bernaudin, Mathieu Kuentz, Leena Karnik, Gérard Socié, Kathryn A. Culos, Robert A. Brodsky, Michael R. DeBaun, Adetola A. Kassim*
- I 210**     **Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies**  
*Rui Ma, Xiao-Jun Huang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Hui Zhang, Chen-Hua Yan, Wei Han, Feng-Rong Wang, Yu-Hong Chen, Huan Chen, Yao Chen, Jing-Zhi Wang, Yu Wang*

## SUPPORTIVE CARE

---

- I218**     **Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation**  
*Mariam T. Nawas, Charalambos Andreadis, Thomas G. Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Lawrence D. Kaplan, Gabriel N. Mannis, Aaron C. Logan, Lloyd E. Damon, Chiung-Yu Huang, Rebecca L. Olin*
- I225**     **New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications**  
*Brian G. Engelhardt, Ujjawal Savani, Dae Kwang Jung, Alvin C. Powers, Madan Jagasia, Heidi Chen, Jason J. Winnick, Robyn A. Tamboli, James E. Crowe Jr, Najj N. Abumrad*
- I232**     **Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant**  
*Alexandra Higgins, Zaraq Khan, Charles C. Coddington, Shahrukh K. Hashmi, Mehrdad Hefazi, Hassan Alkhateeb, Mark R. Litzow, William J. Hogan, Elizabeth Cathcart-Rake, Carrie A. Thompson, Mrinal M. Patnaik*

## SURVIVORSHIP

---

- I240**     **Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health**  
*Colleen M. Morken, Amye J. Tevaarwerk, Amanda K. Swiecichowski, James E. Haine, Zachary T. Williams, Kirsten Norslien, Natalia Arroyo, Xiao Zhang, Bethaney Campbell, Eneida A. Mendonca, Mark B. Juckett, Mary E. Sesto*

## INFECTIOUS DISEASE

---

- I247**     **Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease**  
*Erica Stohs, Victor A. Chow, Catherine Liu, Lori Bourassa, Arianna Miles-Jay, Julie Knight, Ania Sweet, Barry E. Storer, Marco Mielcarek, Steven A. Pergam*
- I253**     **Clinical and Economic Impact of Cytomegalovirus Infection among Children Undergoing Allogeneic Hematopoietic Cell Transplantation**  
*Sonal Rastogi, Angela Ricci, Zhezhen Jin, Monica Bhatia, Diane George, James H. Garvin, Matthew Hall, Prakash Satwani*

## ANALYSIS

---

- I260**     **Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation**  
*Johan Törlén, Ahmed Gaballa, Mats Remberger, Lisa-Mari Mörk, Berit Sundberg, Jonas Mattsson, Michael Uhlin*

## BRIEF ARTICLES

---

- e199**     **Barriers to Allogeneic Hematopoietic Stem Cell Transplantation for Human T Cell Lymphotropic Virus I—Associated Adult T Cell Lymphoma—Leukemia in the United States: Experience from a Large Cohort in a Major Tertiary Center**  
*Diego Adrianzen Herrera, Noah Kornblum, Ana Acuna-Villaorduna, R. Alejandro Sica, Urvi Shah, Moya Butler, Nivetha Vishnuvardhan, Nishi Shah, Lizamarie Bachier-Rodriguez, Olga Derman, Aditi Shastri, Ioannis Mantzaris, Amit K. Verma, Ira Braunschweig, Murali Janakiram*
- e204**     **Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation**  
*Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Christine Wolschke, Renate Arnold, Lothar Kanz, Grant McQuaker, Tony Marchand, Gerard Socié, Jean Henri Bourhis, Mohamad Mohty, Jan J Cornelissen, Patrice Chevallier, Paolo Bernasconi, Matthias Stelljes, Pierre-Simon Rohrlich, Renato Fanin, Jürgen Finke, Johan Maertens, Didier Blaise, Majja Itälä-Remes, Hélène Labussière-Wallet, Marie Robin, Donal McLornan, Yves Chalandon, Ibrahim Yakoub-Agha, Nicolaus Kröger, on behalf of CMWP of the European Society for Blood and Marrow Transplantation*

## LETTERS-TO-THE-EDITOR

---

- e209**     **Comments Regarding “ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells”**  
*Anne Rain T. Brown, Cristina Gutierrez*
- e211**     **Reply**  
*Daniel W. Lee, Elena Mead, Bianca D. Santomasso, Cameron J. Turtle, Stephan A. Grupp, Sattva S. Neelapu*
- e213**     **Pharmacological Considerations in Antithymocyte Globulin Exposure Calculation**  
*Rick Admiraal, Moniek A. de Witte, Alwin Huitema, Stefan Nierkens*
- e216**     **Reply to: Pharmacologic Considerations in Antithymocyte Globulin Exposure Calculation**  
*Kareem Jamani, Shahbal B. Kangarloo, Jan Storek*

## ASTCT NOTES

---

- 1269**     **ASTCT Notes**